{"title": "Dengue Vaccines 2023", "author": "Staff", "url": "https://www.precisionvaccinations.com/dengue-vaccines", "hostname": "precisionvaccinations.com", "description": "Dengue vaccines approved include Dengvaxia and Qdenga", "sitename": "Precision Vaccinations", "date": "2020-01-08", "cleaned_text": "2023 The World Health Organization ( [WHO](https://www.who.int/news-room/questions-and-answers/item/dengue-vaccines)), the U.S. Food and Drug Administration ( [FDA](https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-dengue-disease-endemic-regions)), the U.K. Medicines and Healthcare Products Regulatory Agency ( [MHRA](https://mhraproducts4853.blob.core.windows.net/docs/f92e52062109c86c61e8186dceff26dafbad94c1)), Pan American Health Organization ( [PAHO](https://www.fiercepharma.com/pharma/pan-american-health-organization-early-negotiations-takeda-affordable-dengue-vaccine-price)), the European Medicine Agency ( [EMA](https://www.ema.europa.eu/en/opinion-medicine-use-outside-EU/human/dengue-tetravalent-vaccine-live-attenuated-takeda)), Australia's Technical Advisory Group on Immunisation, and [Brazil's](https://www.health.gov.au/news/clinical-advice-atagi-statement-on-use-of-dengvaxiar-for-australians) National Health Surveillance Agency ( [ANVISA](https://www.gov.br/planalto/en)) have recommended dengue vaccination for persons living or visiting [dengue-risk areas](https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue). Since October 30, 2022, two dengue vaccines have been authorized in various countries. [Market research](https://www.databridgemarketresearch.com/reports/global-dengue-vaccine-market) forecast an 11.7% CAGR through 2030, indicating dengue vaccines will become over a $1.2 billion market segment. [Dengvaxia](https://www.precisionvaccinations.com/vaccines/dengvaxia-dengue-vaccine)\u00ae is a live attenuated tetravalent chimeric vaccine approved by the U.S. FDA and various countries. On June 30, 2023, the FDA issued a [Supplemental Approval](https://www.fda.gov/media/170021/download) letter. [QDENGA\u00ae](https://www.precisionvaccinations.com/vaccines/qdenga-tak-003-dengue-vaccine) is a a humanized monoclonal antibody being evaluated in [phase 2 clinical trials](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111087/) for the treatment of dengue. VIS513 has been shown to be a highly potent inhibitor of all four types of dengue viruses, both in vitro and in preclinical animal models. VIS513 was licensed to the Serum Institute of India Pvt. Ltd ( [SIIPL](https://www.seruminstitute.com/)) for development and commercialization may cost between 5,000 to 10,000 rupees per dose. CEO Poonawalla [stated](https://www.adarpoonawalla.com/develop-dengue-virus.html), \"We expect the government to give a fast-track approval to the application. This is because dengue has become a public health crisis.\" Dengue Vaccine Candidates [Serum Institute of India](https://www.adarpoonawalla.com/develop-dengue-virus.html) tetravalent live candidate [Dengusiil](https://go.drugbank.com/drugs/DB14764/clinical_trials?conditions=DBCOND0121555&phase=1&purpose=prevention&status=completed) is conducting [phase 1 clinical](https://classic.clinicaltrials.gov/ct2/show/NCT04035278) research in Australia. A [study](https://www.sciencedirect.com/science/article/abs/pii/S0264410X23008769) published in August 2023 reported that the vaccine was highly immunogenic, with trivalent or tetravalent seroconversion and seropositivity in most participants. Dengusiil will be commercialized in India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka. National Institute of Allergy and Infectious Diseases - [Phase 1 clinical trial](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204028/) to model primary, secondary, and tertiary dengue using a live attenuated DENV3 monovalent vaccine [rDEN330/31-7164](https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08299-5). This clinical trial will [compare](https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08299-5) the immune responses after primary, secondary, and tertiary DENV exposure in naturally infected humans living in non-endemic areas. A [previous](https://classic.clinicaltrials.gov/ct2/show/NCT01072786) phase I clinical trial, launched in July 2010, was led by principal investigator Anna Durbin, M.D., at Johns Hopkins Bloomberg School of Public Health. The [DV1-DV4](https://www.precisionvaccinations.com/emergex-dengue-fever-dv1-dv4-vaccine-candidate-launch-phase-1-study) vaccine candidate is transitioning into a human clinical study. This new vaccine construct, which comprises Nature's gene-chip peptides bound to a quantum cluster gold nanoparticle delivery system, was shown to have an excellent safety profile in a repeat dose Good Laboratory Practice grade toxicology study using a standard industry model. [TetraVax-DV-TV003](https://www.precisionvaccinations.com/vaccines/tetravax-dv-tv003-dengue-vaccine) (V180) is a live attenuated recombinant tetravalent investigational dengue vaccine conducting a phase 3 clinical trial in Brazil. Dr. Stephen Whitehead's laboratory developed the vaccine at NIH's National Institute of Allergy and Infectious Diseases. [\u00c0vida Biotech's](http://www.avida-biotech.com/) novel oral vaccine candidate for dengue does not require cold transport or storage and has completed proof of concept in a mouse model. In addition, the University of Buffalo's Center for Integrated Global Biomedical Sciences will provide preclinical drug development expertise. [K.M. Biologics KD-382](https://www.kmbiologics.com/en/) vaccine is a live attenuated tetravalent dengue vaccine candidate in [phase 1](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375233) clinical trial that is expected to be effective against all four serotypes with a single dose. In addition, this live attenuated virus vaccine is expected to induce neutralizing antibodies and cellular immunity, similar to natural infection. [Emergex PepGNP-Dengue](https://emergexvaccines.com/pipeline/) vaccine candidate uses 100% synthetic vaccines CTL (CD8+ Cytotoxic T Lymphocyte cells) to kill infected cells before productive viral infection, thus preventing viral replication and disease in the vaccinated person. The Last Visit per [clinical trial protocol](https://clinicaltrials.gov/ct2/show/NCT04935801) was performed in March 2022. Phase I/II and II/III Clinical trials for vaccine candidates are planned. [CodaVax-DENV](https://codagenix.com/pipeline/) is a next-generation tetravalent dengue vaccine candidate under development by Codagenix Inc., whose [vaccine design platform](https://codagenix.com/approach/) has enabled precise and rational attenuation of contemporary serotypes of all four strains of dengue virus through selective codon deoptimization. With this approach, Codagenix can rationally balance all four virus serotypes to produce a safe and highly immunogenic vaccine. Developed by [Panacea Biotech](https://www.panaceabiotec.com/en) in collaboration with the [Indian Council of Medical Research](https://main.icmr.nic.in/content/mandate), the Tetravalent [Panacea](https://www.panaceabiotec.com/en/products/pipeline) dengue vaccine has launched phase l/ll trials in India. [PTI](https://theprint.in/india/phase-3-trial-for-panacea-biotechs-dengue-vaccine-likely-from-aug-sept/1577461/) reported a phase 3 trial is likely to begin in mid-2023. [Indian Immunologicals Limited](https://www.indimmune.com/business-unit/human-health) expects to launch its dengue fever vaccine commercially by 2026. Dengue Vaccine Price Pricing for [Dengvaxia\u00ae is about $99](https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html) in the USA. In addition, the CDC's [Vaccine for Children](https://www.cdc.gov/vaccines/programs/vfc/index.html) fund supports eligible people. And [UNICEF](https://supply.unicef.org/) offers various support programs worldwide. Additional vaccine price information is posted at [InstantRx](https://www.precisionvaccinations.com/vaccine-discounts-and-price). Dengue Outbreaks 2023 For the latest travel alerts regarding dengue outbreaks in 2023, visit [Vax-Before-Travel.com/Dengue](https://www.vaxbeforetravel.com/dengue-vaccines). Dengue Vaccine News 2023 [July 3, 2023](https://www.fda.gov/vaccines-blood-biologics/dengvaxia) - The Vaccine, CDC's ACIP Workgroup presentations. [May 22, 2023](https://www.portugalresident.com/portugal-has-new-vaccine-against-all-types-of-dengue/) - Portugal's Institute Hygiene and Tropical Medicine authorized Qdenga. [March 13, 2023](https://www.takeda.com/newsroom/newsreleases/2023/takedas-qdenga-approved-in-brazil) - Brazil authorized the Qdenga vaccine. [February 6, 2023](https://www.prnewswire.co.uk/news-releases/takeda-uk-ltd-announces-mhra-approval-for-dengue-virus-vaccine-candidate-qdenga-301739438.html) - The U.K.'s MHRA granted authorization for Takeda's vaccine candidate Qdenga\u00ae. [January 28, 2023](https://news.co.cr/dengue-vaccine-already-available-pharmacies-costa-rica/53295/) - Costa Rica local media confirmed the Dengvaxia vaccine was commercially available at pharmacies. [December 16, 2022](https://butantan.gov.br/noticias/vacina-da-dengue-do-butantan-tem-eficacia-de-796-mostram-primeiros-resultados-da-fase-3) - The dengue vaccine (V180) developed by the Butantan Institute (Butantan-DV) was found to be 79.6% effective in preventing the disease in Brazil, according to a phase 3 clinical study. [October 14, 2022](https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022) - Europe's human medicines committee recommended granting marketing authorization for the QDENGA Dengue Tetravalent Vaccine (Live, for the prevention of dengue virus, serotypes 1, 2, 3, and 4 in people from four years of age. [August 22, 2022](https://www.businesswire.com/news/home/20220822005454/en/Takeda%E2%80%99s-QDENGA%C2%AE%E2%96%BC-Dengue-Tetravalent-Vaccine-Live-Attenuated-Approved-in-Indonesia-for-Use-Regardless-of-Prior-Dengue-Exposure) - The Indonesia National Agency for Drug and Food Control, [Badan Pengawas Obat dan Makanan](https://www.pom.go.id/new/), 17, 2022](https://www.prnewswire.com/news-releases/codagenix-announces-award-with-the-us-department-of-defense-for-development-of-balanced-tetravalent-dengue-vaccine-301607120.html) - Codagenix Inc. announced the U.S. DoD granted the Company a $4.4 million award to progress the development of CodaVax-DENV, its tetravalent dengue vaccine candidate. [July 1, 2022](https://www.globenewswire.com/news-release/2022/07/01/2472615/0/en/Emergex-Vaccines-signs-Heads-of-Terms-for-a-Collaboration-with-Molecular-Biology-Institute-of-Paran%C3%A1-IBMP-in-Brazil.html) - Emergex Vaccines Holding Limited announced that it had signed heads of terms for a collaboration with the Molecular Biology Institute of Paran\u00e1, focusing on dengue vaccinations. [June 9, 2022](https://www.takeda.com/newsroom/newsreleases/2022/takedas-dengue-vaccine-candidate-provides-continued-protection-against-dengue-fever-through-4.5-years-in-pivotal-clinical-trial/) - Takeda's TAK-003 is Undergoing Regulatory Review for Potential Licensure in the European Union and Select Dengue-Endemic Countries. [April 18, 2022](https://emergexvaccines.com/emergex-provides-an-update-on-first-in-human-studies-of-its-novel-dengue-fever-and-coronavirus-t-cell-adaptive-vaccines/) - Emergex Vaccines Holding Limited updated its first-in-human clinical trials of its Dengue and Coronavirus T cell Adaptive Vaccine candidates. In addition, the Company completed the [Phase I ](https://clinicaltrials.gov/ct2/show/NCT04935801)clinical trial for its novel CD8+ T cell Dengue vaccine candidate. [October 4, 2021](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab864/6381105) - Clinical Infectious Diseases published: Three years efficacy and safety of Takeda's dengue vaccine candidate (TAK-003), which concluded by stating 'TAK-003 was efficacious against symptomatic dengue over three years. Efficacy declined over time but remained robust against hospitalized dengue.' [August 23, 2019](https://www.sciencedirect.com/science/article/pii/S0264410X19308941?via%3Dihub) - Study: Pre-vaccination screening strategies for using the CYD-TDV dengue vaccine: A meeting report. The meeting discussions highlighted many challenges in introducing Dengvaxia, screening test characteristics, costs of such tests combined with a 3-dose schedule, logistics, high coverage rates, vaccine confidence, and communication; more challenges than any other vaccine introduction program. [November 14, 2018](https://www.healio.com/news/pediatrics/20181113/takeda-dengue-vaccine-candidate-may-prevent-all-four-serotypes) - Preliminary data regarding a live-attenuated tetravalent dengue vaccine candidate developed by Takeda show that the vaccine may protect against all four serotypes of the infection, according to research presented at the annual meeting of the American Society of Tropical Medicine and Hygiene. Note: The content on this webpage is aggregated from the WHO, the U.S. CDC, research studies, and various media sources. Healthcare providers like Dr. Bob Carlso review this content for efficacy. "}